Marshall Urist Sells 13,684 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 13,684 shares of the firm’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04. Following the transaction, the executive vice president directly owned 31,881 shares in the company, valued at $1,691,605.86. This trade represents a 30.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Royalty Pharma Stock Down 1.0%

NASDAQ RPRX traded down $0.55 during trading on Friday, reaching $52.85. 4,264,710 shares of the company’s stock traded hands, compared to its average volume of 3,562,113. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The firm has a market cap of $30.43 billion, a price-to-earnings ratio of 35.95, a price-to-earnings-growth ratio of 1.46 and a beta of 0.40. The company’s 50 day simple moving average is $48.20 and its two-hundred day simple moving average is $43.28. Royalty Pharma PLC has a 12-month low of $32.15 and a 12-month high of $53.47.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The business had revenue of $631.00 million for the quarter, compared to analysts’ expectations of $881.69 million. As a group, sell-side analysts forecast that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Analyst Ratings Changes

RPRX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Morgan Stanley raised their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $53.71.

Institutional Trading of Royalty Pharma

A number of institutional investors have recently bought and sold shares of RPRX. Morgan Stanley boosted its stake in Royalty Pharma by 25.2% in the 4th quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock worth $2,135,790,000 after purchasing an additional 11,110,115 shares in the last quarter. Capital International Investors boosted its stake in Royalty Pharma by 24.4% in the 3rd quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock worth $960,064,000 after purchasing an additional 5,332,074 shares in the last quarter. Norges Bank acquired a new stake in Royalty Pharma in the 4th quarter worth approximately $131,923,000. Dorsey Asset Management LLC acquired a new stake in Royalty Pharma in the 3rd quarter worth approximately $82,924,000. Finally, Qube Research & Technologies Ltd boosted its stake in Royalty Pharma by 737.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company’s stock worth $87,557,000 after purchasing an additional 2,185,366 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.